TICKERNERD
Menu
BJDXBJDXHealthcare · Medical Devices

BJDX Stock Forecast: Bluejay Diagnostics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$0.92
−2.30% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 20 of 100 as at 22 Aug 2026 — in the weakest quartile.

Market cap
$942,521.00
Ticker Nerd rank
20 / 100
Median analyst target
—
Analysts covering
0
Total return, dividends reinvested
1W
−12.6%
1M
−20.9%
YTD
−65.6%
1Y
−82.9%
From 52W high
−93.4%
From 52W low
+6.7%
$1
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BJDX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Bluejay Diagnostics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
20 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
98
Accruals
73
Volatility
64
Momentum
35
Issuance
33
Growth
27
Revisions
25
Quality
9
Value
2

Size (98): Smaller than most of the companies we track.

Value (2): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BJDX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BJDX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$2$4$6$8$10$12$14Oct 25Jan 26Apr 26Jul 26BJDX

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
3 Aug 2023Dawson JamesDowngradeNeutral—
12 Jan 2022Dawson JamesInitiatesBuy$10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BJDX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

BJDX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Bluejay Diagnostics, Inc. (BJDX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 75% of US stocks

Price / sales
—
Price / book
0.2×

Cheaper than 90% of US stocks

EV / EBITDA
0.8×

Cheaper than 58% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−98.9%

Higher than 13% of US stocks

Return on assets
−51.1%

Higher than 8% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

BJDX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
BJDXBluejay Diagnostics, Inc.$942,521.00
20
NUWENuwellis, Inc.$4.2M
17
FEEDENvue Medical, Inc.$4.3M
23
GCTKGlucoTrack, Inc.$3.7M
10
TNONTENON Medical, Inc.$4.6M
55
POASPhaos Technology Holdings (Cayman) Ltd.$4.6M
2
XAIRBeyond Air, Inc.$4.8M
38

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Bluejay Diagnostics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BJDX news & analysis

Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization

GlobeNewsWire · 13 Aug 2026positive

Bluejay Diagnostics reported its financial results for the quarter ended June 30, 2026, and provided an update on its clinical, regulatory and manufacturing progress. The company said its strengthened balance sheet supports advancement of the Symphony™ IL-6 test toward regulatory submission and commercialization.

Why it matters — A BJDX watcher would care because the update addresses the company's clinical, regulatory and manufacturing progress toward bringing Symphony™ IL-6 to regulatory submission and commercialization.

FAQ

Frequently asked questions about BJDX stock

How does Ticker Nerd's model rank BJDX?

As at 22 Aug 2026, Bluejay Diagnostics, Inc. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).

What is the BJDX stock forecast for 2030?

No analyst covering Bluejay Diagnostics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BJDX are extrapolating price history, which says nothing about the business.

How has BJDX stock performed over the past year?

Bluejay Diagnostics, Inc. returned -82.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Bluejay Diagnostics, Inc. do?

Bluejay Diagnostics Inc. is a medical technology company focused on developing and marketing rapid diagnostic solutions for use in clinical settings.

What is the latest news on BJDX?

The most recent item we track (GlobeNewsWire, 13 Aug 2026): "Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization". Bluejay Diagnostics reported its financial results for the quarter ended June 30, 2026, and provided an update on its clinical, regulatory and manufacturing progress. The company said its strengthened balance sheet supports advancement of the Symphony™ IL-6 test toward regulatory submission and commercialization.

Company

About Bluejay Diagnostics, Inc.

Bluejay Diagnostics Inc. is a medical technology company focused on developing and marketing rapid diagnostic solutions for use in clinical settings. The company specializes in minimally invasive point-of-care tests and devices designed to provide timely, lab-quality biomarker results near the patient, supporting faster clinical decision-making in critical care environments. Its flagship Symphony platform is a near-patient biomarker detection system aimed at conditions where early and precise measurement of inflammatory and infectious markers can guide treatment. Bluejay Diagnostics primarily targets the infectious disease, inflammation, and oncology markets, working to enable more efficient triage and monitoring of patients in emergency departments, intensive care units, and other acute-care settings. Headquartered in Acton, Massachusetts and founded in 2015, the company operates within the health technology sector and the medical specialties industry, serving healthcare providers seeking to streamline workflows and improve access to actionable diagnostic information at or near the point of care.

CEO Mr. Indranil Dey · 6 employees · United States · https://bluejaydx.com